Agomab Posts EUR252M Cash, Confirms 2026 Outlook with Key Catalysts Ahead
AGMB sits 54% above its 52-week low of $8.75.
Summary
Agomab reported half-year 2026 financials with EUR252 million in cash, including $208 million from its recent IPO, extending runway into the first half of 2029. The company confirmed its 2026 outlook, highlighting upcoming topline data from the STENOVA OLE study in fibrostenosing Crohn's disease and first IPF data for AGMB-447 in the coming months. The NOV-ERA Phase 2b study for ontunisertib, aligned with the FDA on a novel primary endpoint, is on track to initiate in the second half of 2026. This follows the June 2026 announcement of the FDA agreement on the NOV-ERA design, adding financial context and a clear timeline for multiple near-term readouts. The strong cash position and catalyst-rich second half position the company for significant value inflection.
At the time of this announcement, AGMB was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $697.9M. The 52-week trading range was $8.75 to $17.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.